Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the product listed below.
| NDC | Partner Therapeutics Product | Dosage Form | Strength | Unit Size | Wholesale Acquisition Cost |
|---|---|---|---|---|---|
| 71837-5843-05 | LEUKINE® | Vial | 250 mcg | 5 vial pack | $1,573.14* |
The price paid by patients to acquire the product listed is often different than the WAC price listed, and most patients do not pay WAC. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company or preferred pharmacy
Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” In Colorado, LEUKINE falls within the Hematopoietic agent class which includes the G-CSF biosimilars including Nivestim™ (Filgrastim (rbe)), RELEUKO® (Filgrastim-ayow) and ZARXIO® (filgrastim sndz),
*Pricing as of July 1, 2025. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates or reductions in price. Pricing information listed does not imply safety or efficacy of the product.
LEUKINE is a registered trademark licensed to Partner Therapeutics, Inc.
Nivestim is a trademark of Pfizer Inc.
RELEUKI is a registered trademark of Amneal Pharmaceutics, LLC.
ZARXIO is a registered trademark of Novartis AG